NEW YORK (GenomeWeb News) – Thermo Fisher Scientific today reported 14 percent growth in revenues year over year for the first quarter as the Analytical Technologies and Specialty Diagnostics segments each grew more than 20 percent.

For the period ended March 31, total revenues rose to $3.10 billion from $2.72 billion, besting Wall Street estimates of $2.98 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.